PubMed Health⌕ Search

PubMed · 9712470

Improved solid-phase extraction technique for plasma flecainide analysis by high-performance liquid chromatography.

Abstract

A method for analyzing flecainide in plasma was developed and assessed. Based on the use of C18 extraction columns eight or fewer times, the rapid and simple extraction procedure provided consistent, high-efficiency flecainide extraction (>85%). Using reverse-phase, high-performance liquid chromatography with fluorometric detection, flecainide acetate was detectable to approximately 15 ng/ml. Retention times of the internal standard and flecainide were 8.9 to 9.2 and 9.8 to 10.4 minutes, respectively, and short sample preparation and run times enabled results to be delivered within 2 to 3 hours of receiving samples. The assay was linear for the standard range 20 ng/ml to 2 microg/ml (r2 with three standards, >0.999) and delivered a high level of accuracy. Quality control concentrations obtained from eight assays consistently fell within 5% of nominal values (100 ng/ml and 1 microg/ml). Based on four assays, the assay was also reproducible with calculated-between and within-assay coefficients of variation of less than 1% and 3%, respectively. The authors found that the performance of this assay was excellent and that the solid-phase extraction technique was simple, rapid, and cost effective.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K M Wilson, J J Schneider, P J Ravenscroft. 1998. Improved solid-phase extraction technique for plasma flecainide analysis by high-performance liquid chromatography.. https://doi.org/10.1097/00007691-199808000-00014

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Sotalol in the treatment of fetal dysrhythmias.

BACKGROUND: Fetal tachycardia may cause hydrops fetalis and lead to fetal death. No unanimity of opinion exists regarding the optimum treatment. This study evaluates our experience with transplacental sotalol therapy to treat fetal tachycardias in terms of safety and efficacy. METHODS AND RESULTS: The charts of 21 patients who were treated with sotalol for fetal tachycardia were reviewed. Ten fetuses had atrial flutter (AF), 10 had supraventricular tachycardia (SVT), and 1 had VT. Hydrops fetalis was present in 9 fetuses. Drug treatment was successful in establishing sinus rhythm in 8 of 10 fetuses with AF and in 6 of 10 fetuses with SVT. The mortality rate in this study was 19% (4 of 21 fetuses; 3 had SVT and 1 had AF); 3 deaths occurred just days after the initiation of sotalol therapy, and 1 occurred after a dosage increase. At birth, tachycardia was present in 6 infants. Two patients who converted to sinus rhythm in utero suffered from neurologic pathology postnatally. CONCLUSIONS: Fetal tachycardia is a serious condition in which treatment should be initiated, especially in the presence of hydrops fetalis. The high success rate in fetuses with AF suggests that sotalol should be considered a drug of first choice to treat fetal AF. The low conversion rate and the fact that 3 of the 4 deaths in this study occurred in fetuses with SVT indicate that the risks of sotalol therapy outweigh the benefits in this group and that sotalol should, therefore, be limited in the treatment of fetal SVT.

Anti-Arrhythmia Agents↗